Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2020 08:19 ET | Source: Biomerica, Inc.

Biomerica Reports Fiscal Year End May 31, 2020 Financial Results

Fiscal fourth quarter revenues increase 133.7% over the prior yearFiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 ...
August 31, 2020 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors

IRVINE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of...
August 12, 2020 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests

IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s...
July 22, 2020 06:39 ET | Source: Biomerica, Inc.

Biomerica Announces Filing of New Three Year Shelf Registration Statement

IRVINE, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has filed a new three year shelf registration statement on Form S-3 with the United States...
June 29, 2020 21:39 ET | Source: Biomerica, Inc.

The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial

InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...
June 16, 2020 08:19 ET | Source: Biomerica, Inc.

Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19

This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced...
June 01, 2020 07:38 ET | Source: Biomerica, Inc.

Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial

Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology InFoods® Diagnostic-Guided Therapy is designed to identify...
May 07, 2020 06:36 ET | Source: Biomerica, Inc.

Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution

New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by...
April 15, 2020 08:30 ET | Source: Biomerica, Inc.

Biomerica Announces Third Quarter Financial Results

IRVINE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $3,967,712 for the nine months ending February 29, 2020, compared to $4,034,822 for the...
April 02, 2020 07:38 ET | Source: Biomerica, Inc.

Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs

Price point of this high-volume laboratory version test is expected be as low as $10 per patient Once developed and scaled-up, Biomerica’s existing production capacity could allow for over 1,000,000...